2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168159
    TLR7 agonist 27 98%
    TLR7 agonist 27 (compound 24) is a potent TLR7 agonist with an EC50 of 238.1 nM. TLR7 agonist 27 shows weak agonistic activity against NOD2 (nucleotide-binding oligomerization domain 2) (EC50 of 6.2 μM). TLR7 agonist 27 is a potent immunostimulant, and can be used as a vaccine adjuvant and/or immunotherapeutic.
    TLR7 agonist 27
  • HY-168179
    RORγt inverse agonist 32 2301159-96-4 98%
    RORγt inverse agonist 32 (compound b14) is orally active. RORγt inverse agonist 32 can be used in inflammation research.
    RORγt inverse agonist 32
  • HY-168207
    TH023 98%
    TH023 is an inhibitor for the TLR4 signaling pathway, that targets especially the formation of TLR4 homodimer. TH023 inhibits secreted embryonic alkaline phosphatase in cell HEK-Blue hTLR4 with an IC50 of 0.354 μM, and inhibits the NO expression in RAW264.7 with an IC50 of 1.61μM. TH023 also inhibits the activation of NF-κB, reduces the nuclear translocation of NF-κB p65. TH023 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced mouse acute sepsis model, and ameliorates the mouse lung injury.
    TH023
  • HY-168212
    PDE4-IN-22 98%
    PDE4-IN-22 (Compound 2e) is a PDE4 inhibitor with an IC50 value of 2.4 nM. PDE4-IN-22 exhibits anti-inflammatory activity and demonstrates significant anti-psoriatic effects in an Imiquimod (HY-B0180)-induced psoriasis mouse model.
    PDE4-IN-22
  • HY-168300
    Antiangiogenic agent 7 2527888-07-7 98%
    Antiangiogenic agent 7 (Compound 1) can induce cell apoptosis, increase Reactive Oxygen Species, and inhibit the intracellular enzyme thioredoxin reductase. Antiangiogenic agent 7 has anti-cancer activity, with an IC50 of 0.08-3.5 μM against cervical cancer cells HeLa, prostate cancer cells PC-3, and non-small cell lung cancer A549. Antiangiogenic agent 7 inhibits tumor growth in mouse xenograft models.
    Antiangiogenic agent 7
  • HY-168327
    LH10 98%
    LH10 is a fexaramine-based agonist for FXR with an EC50 of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models.
    LH10
  • HY-168339
    Tyk2-IN-22 933667-23-3 98%
    Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits Tyk2, JAK1, and JAK3 with IC50s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation.
    Tyk2-IN-22
  • HY-168340
    COX-2/15-LOX-IN-6 98%
    COX-2/15-LOX-IN-6 (Compound 5l) is the dual inhibitor for COX-2 and 15-LOX, with IC50 of 0.201 μM and 11.723 μM. COX-2/15-LOX-IN-6 inhibits the expression of PGE, TNF-α, IL-6 and iNOS in serum, and exhibits anti-inflammatory effect in Carrageenan (HY-125474)-induced rats edema model.
    COX-2/15-LOX-IN-6
  • HY-168341
    sGC activator 2 98%
    sGC activator 2 (Compound 16a) is an activator for soluble guanylate cyclase (sGC), that promotes the cGMP production and exhibits vascular protective and anti-inflammatory activities.
    sGC activator 2
  • HY-168344
    CACPD2011a-0001278239 1030781-08-8 98%
    CACPD2011a-0001278239 is a β2AR mixed agonist that shows a wide range of high-affinity binding to both wild-type and T164I β2AR variants, with no cytotoxicity or mutagenicity, making it suitable for asthma research.
    CACPD2011a-0001278239
  • HY-168370
    YHS-12 2959463-68-2 98%
    YHS-12 is an ionizable cationic lipid, which can be used to synthesize lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA.
    YHS-12
  • HY-168383
    (E/Z)-Resomelagon acetate 959850-74-9 98%
    (E/Z)-Resomelagon acetate is an agonist of melanocortin receptor 1 (MC1R) and MC3R with anti-inflammatory activities. (E/Z)-Resomelagon can be utilized in inflammation research.
    (E/Z)-Resomelagon acetate
  • HY-168466
    Anti-neuroinflammation agent 2 3040102-76-6 98%
    Anti-neuroinflammation agent 2 (compound 4) demonstrates anti-neuroinflammatory and antibacterial activities, with IC50 values of 3.06 µM for TNF-α and 4.31 µM for IL-6, alongside EC50 values ranging from 0.87 to 3.16 µM against Gram-positive bacteria.
    Anti-neuroinflammation agent 2
  • HY-168471
    AAL-149 177258-60-5 98%
    AAL-149 is a FTY720 (HY-12005) analog and TRPM7 inhibitor (IC50 = 1.081 μM) with multimodal anti-inflammatory effects and without targeting S1P receptors. AAL-149 can be utilized in anti-inflammatory research.
    AAL-149
  • HY-168474
    P2X4 antagonist-4 98%
    P2X4 antagonist-4 (compound 64) is a potent P2X4R antagonist with an IC50 value of 8 µM. P2X4 antagonist-4 blocks the ATP-induced NLRP3 inflammasome activation and release of IL-1β.
    P2X4 antagonist-4
  • HY-168484
    T-10430 98%
    T-10430 is a potent and orally active leukotriene B4 receptor 2 (BLT2) agonist. T-10430 has the potential for the research of psoriasis.
    T-10430
  • HY-168501
    Neuroprotective agent 6 98%
    Neuroprotective Agent 6 (Compound Y12) is a neuroprotective agent with antioxidant activity and capabilities in DPPH, ABTS radical scavenging. Neuroprotective Agent 6 demonstrates superior neuroprotective effects in both cellular models induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and animal models induced by transient middle cerebral artery occlusion (tMCAO). Additionally, Neuroprotective Agent 6 exhibits significant metal chelating activity towards Cu2+.
    Neuroprotective agent 6
  • HY-168503
    NLRP3-IN-54 98%
    NLRP3-IN-54 (Compound C4) is an NLRP3 inhibitor. NLRP3-IN-54 can significantly reduce the levels of active Caspase-1 and active IL-1β (IC50 = 0.805 μM), can be used for inflammation research.
    NLRP3-IN-54
  • HY-168521
    αvβ6-IN-1 98%
    αvβ6-IN-1 (compound 28) is a potent and orally active αvβ6 integrin inhibitor with a pIC50 value of 8.1. αvβ6-IN-1 has the potential for the research of idiopathic pulmonary fibrosis.
    αvβ6-IN-1
  • HY-168522
    αvβ6-IN-2 98%
    αvβ6-IN-2 (compound 20) is a potent and orally active αvβ6 integrin inhibitor with a pIC50 value of 7.8. αvβ6-IN-2 has the potential for the research of idiopathic pulmonary fibrosis.
    αvβ6-IN-2
Cat. No. Product Name / Synonyms Application Reactivity